COHANCE Stock Overview
Cohance Lifesciences Limited engage in the end-to-end contract development and manufacturing of intermediates and active pharmaceutical ingredients in India. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 5/6 |
| Past Performance | 1/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for COHANCE from our risk checks.
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Cohance Lifesciences Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹1,079.20 |
| 52 Week High | ₹1,360.00 |
| 52 Week Low | ₹598.00 |
| Beta | 1.13 |
| 1 Month Change | -7.61% |
| 3 Month Change | -0.96% |
| 1 Year Change | 67.14% |
| 3 Year Change | 106.74% |
| 5 Year Change | 571.14% |
| Change since IPO | 540.38% |
Recent News & Updates
Recent updates
Converting Increased RFPs Into Contracts Will Strengthen Future Prospects
Feb 23 Strategic acquisitions and diversification into niche markets enhance Suven's revenue potential and improve margins through high-value offerings.These 4 Measures Indicate That Suven Pharmaceuticals (NSE:SUVENPHAR) Is Using Debt Safely
Dec 15
Robust Earnings May Not Tell The Whole Story For Suven Pharmaceuticals (NSE:SUVENPHAR)
Aug 03Does Suven Pharmaceuticals (NSE:SUVENPHAR) Have A Healthy Balance Sheet?
May 12Suven Pharmaceuticals Limited (NSE:SUVENPHAR) Investors Are Less Pessimistic Than Expected
Mar 26Here's Why We Think Suven Pharmaceuticals (NSE:SUVENPHAR) Is Well Worth Watching
Mar 07These 4 Measures Indicate That Suven Pharmaceuticals (NSE:SUVENPHAR) Is Using Debt Safely
Nov 30Do Suven Pharmaceuticals's (NSE:SUVENPHAR) Earnings Warrant Your Attention?
Sep 03Here's Why Suven Pharmaceuticals (NSE:SUVENPHAR) Can Manage Its Debt Responsibly
Aug 04Analysts Have Made A Financial Statement On Suven Pharmaceuticals Limited's (NSE:SUVENPHAR) Full-Year Report
Jun 11With EPS Growth And More, Suven Pharmaceuticals (NSE:SUVENPHAR) Is Interesting
Apr 13Does Suven Pharmaceuticals (NSE:SUVENPHAR) Have A Healthy Balance Sheet?
Mar 08Can Suven Pharmaceuticals Limited's (NSE:SUVENPHAR) ROE Continue To Surpass The Industry Average?
Feb 08Shareholder Returns
| COHANCE | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | 0.1% | 2.7% | 6.3% |
| 1Y | 67.1% | 13.0% | 4.6% |
Return vs Industry: COHANCE exceeded the Indian Pharmaceuticals industry which returned 13% over the past year.
Return vs Market: COHANCE exceeded the Indian Market which returned 4.6% over the past year.
Price Volatility
| COHANCE volatility | |
|---|---|
| COHANCE Average Weekly Movement | 6.4% |
| Pharmaceuticals Industry Average Movement | 7.2% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in IN Market | 9.8% |
| 10% least volatile stocks in IN Market | 4.7% |
Stable Share Price: COHANCE has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: COHANCE's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1989 | n/a | Sudhir Singh | www.cohance.com |
Cohance Lifesciences Limited engage in the end-to-end contract development and manufacturing of intermediates and active pharmaceutical ingredients in India. The coampny offers active pharmaceutical ingredients and formulations for various applications; CDMO services, a flexible and custom solutions for challenging development and manufacturing needs; and clinical, analytical, and research services. It also manufactures finished dosage formulations for pharmaceutical companies; and specialty chemicals, such as electronic chemicals.
Cohance Lifesciences Limited Fundamentals Summary
| COHANCE fundamental statistics | |
|---|---|
| Market cap | ₹274.73b |
| Earnings (TTM) | ₹2.79b |
| Revenue (TTM) | ₹10.48b |
98.4x
P/E Ratio26.2x
P/S RatioIs COHANCE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| COHANCE income statement (TTM) | |
|---|---|
| Revenue | ₹10.48b |
| Cost of Revenue | ₹3.90b |
| Gross Profit | ₹6.58b |
| Other Expenses | ₹3.79b |
| Earnings | ₹2.79b |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
May 28, 2025
| Earnings per share (EPS) | 10.97 |
| Gross Margin | 62.78% |
| Net Profit Margin | 26.63% |
| Debt/Equity Ratio | 1.9% |
How did COHANCE perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/17 18:39 |
| End of Day Share Price | 2025/05/16 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Cohance Lifesciences Limited is covered by 10 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Vijayaraghavan Swaminathan | Avendus Spark |
| Harith Ahamed | Avendus Spark |
| Rohit Bhat | Batlivala & Karani Securities India Pvt. Ltd. |